Register
Forgot your password?

Biochemical markers of endothelial dysfunction in patients with coarctation of the aorta after surgery

Authors: Svobodov A.A., Levchenko E.G., Chernenko M.I.

Company: Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russian Federation

For correspondence:  Sign in or register.

Type:  Reviews


DOI: https://doi.org/10.24022/1997-3187-2023-17-4-474-480

For citation: Svobodov A.A., Levchenko E.G., Chernenko M.I. Biochemical markers of endothelial dysfunction in patients with coarctation of the aorta after surgery. Creative Cardiology. 2023; 17 (4): 474–80 (in Russ.). DOI: 10.24022/1997-3187-2023-17-4-474-480

Received / Accepted:  27.02.2023 / 08.11.2023

Keywords: biomarkers coarctation of the aorta asymmetric dimethylarginine sE-selectin galectin-3 syndecan-1 matrix metallopeptidase 9 renin angiotensin aldosterone children congenital heart disease

Download
Full text:  

 

Abstract

Coarctation of the aorta (CoAo) is a common congenital heart defect that lends itself well to radical surgical correction. However, in the long term, patients after CoAo repair often experience other cardiovascular diseases such as arterial hypertension, aortic arch remodelling, early atherosclerosis, chronic coronary syndrome and others. The genesis of these diseases is associated with the presence of CoAo and generalised vasculopathy, which is a consequence of endothelial dysfunction. The latter is a complex and poorly understood process, known only by indirect signs such as special molecules appearing in the blood in cases of apparent endotheliopathy. This is article review of biochemical markers of endothelial dysfunction before and after the correction of coarctation of the aorta is presented, both common markers of endothelial dysfunction (asymmetric dimethylarginine (ADMA), sE-selectin, galectin-3), and molecules probably associated with it (RAAS enzymes, syndecan-1, matrix metallopeptidase 9) are reviewed.

References

  1. Canniffe C., Ou P., Walsh K., Bonnet D., Celemajer D. Hypertension after repair of aortic coarctation – a systematic review. Int. J. Cardiol. 2013; 167 (6): 2456–61. DOI: 10.1016/j.ijcard.2012.09.084
  2. Bhatt A.B., Yeh D.D. Long-term outcomes in coarctation of the aorta: an evolving story of success and new challenges. Heart. 2015; 101 (15): 1173–5. DOI: 10.1136/heartjnl-2015-307641
  3. Soynov I.A., Sinelnikov Yu.S., Gorbatykh A.V., Nichay N.R., Ivantsov S.M., Kornilov I.A., Kshanovskaya M.S., Gorbatykh Yu.N. Arterial hypertension in patients after correction of coarctation and hypoplasia of the aortic arch. Circulation Pathology and Cardiac Surgery (Patologiya Krovoobrashcheniya i Kardiokhirurgiya). 2015; 19 (2): 102–12 (in Russ.).
  4. Hlebowicz J., Holm J., Lindstedt S., Goncalves I., Nilsson J. Carotid atherosclerosis, changes in tissue remodeling and repair in patients with aortic coarctation. Atherosclerosis. 2021; 335: 47–52. DOI: 10.1016/j.atherosclerosis.2021.09.016
  5. Mizia-Stec K., Trojnarska О., Szczepaniak-Chicheł L., Gabriel M., Bartczak A., Ciepłucha A., Chudek J. et al. Asymmetric dimethylarginine and vascular indices of atherosclerosis in patients after coarctation of aorta repair. Int. J. Cardiol. 2012; 158: 364–9. DOI: 10.1016/j.ijcard.2011.01.037
  6. Jenkins N.P., Ward C. Coarctation of the aorta: natural history and outcome after surgical treatment. Q. J. Med. 1999; 92: 365– 71. DOI: 10.1093/qjmed/92.7.365
  7. Brown M.L., Burkhart H.M., Connolly H.M., Dearani J.A., Cetta F., Li Z., Oliver W.C. et al. Coarctation of the aorta: lifelong surveillance is mandatory following surgical repair. J. Am. Coll. Cardiol. 2013; 62: 1020–5. DOI: 10.1016/j.jacc.2013.06.016
  8. Gidding S.S., Rocchini A., Moorehead C., Schork M., Rosenthal A. Increased forearm vascular reactivity in patients with hypertension after repair of coarctation. Circulation. 1985; 71 (3): 495–9. DOI: 10.1161/01.cir.71.3.495
  9. Ou P., Celermajer D., Mousseaux E., Giron A., Aggoun Y., Szezepanski I., Sidi D. et al. Vascular remodelling after successful repair of coarctation. J. Am. Coll. Cardiol. 2007; 49 (8): 883–90. DOI: 10.1016/j.jacc.2006.10.057
  10. Lee M.G.Y., Babu-Narayan S.V., Kempny A., Uebing A., Montanaro C., Shore D.F., d’Udekem Y. et al. Long-term mortality and cardiovascular burden for adult survivors of coarctation of the aorta. Heart. 2019; 105 (15): 1190–6. DOI: 10.1136/heartjnl-2018-314257
  11. Lee M.G.Y., Hemmes R.A., Mynard J., Lambert E., Head G.A., Cheung M.M.H., Konstantinov I.E. et al. Elevated sympathetic activity, endothelial dysfunction, and late hypertension after repair of coarctation of the aorta. Int. J. Cardiol. 2017; 243: 185– 90. DOI: 10.1016/j.ijcard.2017.05.075
  12. Todorov S.S. Pathomorphological characteristics of changes in the aorta during coarctation in children of the first year of life. Journal of VolgSMU. 2009; 3: 73–7 (in Russ.).
  13. Menon A., Eddinger T.J.,Wang H., Wendell D.C., Toth J.M., LaDisa J.F. Altered hemodynamics, endothelial function and protein expression occur with aortic coarctation and persist following repair. Am. J. Physiol. Heart Circ. Physiol. 2012; 303 (11): H1304–18. DOI: 10.1152/ajpheart.00420.2012
  14. Tumanyan M.R., Svobodov A.A., Levchenko E.G., Kupryashov A.A., Kotova A.N. Cardiac biomarkers in newborns and young children with congenital heart defects. Pediatria. Journal named after G.N. Speransky. 2022; 101 (3): 178–84 (in Russ.). DOI: 10.24110/0031-403X-2022-101-3-178-184
  15. Konukoglu D., Uzun H. Endothelial dysfunction and hypertension. Adv. Exp. Med. Biol. 2017; 956: 511–40. DOI: 10.1007/5584_2016_90
  16. Blackwell S. The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine. Ann. Clin. Biochem. 2010; 47 (1): 17–28. DOI: 10.1258/acb.2009.009196
  17. Mizia-Stec K., Trojnarska O., Szczepaniak-Chicheł L., Gabriel M., Bartczak A., Ciepłucha A. et al. Asymmetric dimethylarginine and vascular indices of atherosclerosis in patients after coarctation of aorta repair. Int. J. Cardiol. 2012; 158 (3): 364–9. DOI: 10.1016/j.ijcard.2011.01.037
  18. Németh B., Ajtay Z., Hejjel L., Ferenci T., Abram Z., Muranyi E. et al. The issue of plasma asymmetric dimethylarginine reference range – A systematic review and meta-analysis. PLoS ONE. 2017; 12 (5): e0177493. DOI: 10.1371/journal.pone.0177493
  19. Mikhno V.A., Bogomolova I.K. Study of the level of asymmetric dimethylarginine in healthy children. Tyumen Medical Journal. 2011; 2 (in Russ.).
  20. Roldán V., Marín F., Lip Y.H.G., Blann A.D. Soluble E-selectin in cardiovascular disease and its risk factors. Thromb. Haemost. 2003; 90 (6): 1007–20. DOI: 10.1160/TH02-09-0083
  21. Glowinska B., Urban M., Peczynska J., Florys B. Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity, hypertension, and diabetes. Met. Clin. Exp. 2005; 54 (8): 1020–6. DOI: 10.1016/j.metabol.2005.03.004
  22. Brili S., Tousoulis D., Antoniades Ch., Aggeli C., Roubelakis A., Papathanasiu S., Stefanadis Ch. Evidence of vascular dysfunction in young patients with successfully repaired coarctation of aorta. Atherosclerosis. 2005; 182 (1): 97–103. DOI: 10.1016/j.atherosclerosis.2005.01.030
  23. Osmancik P., Bocsi J., Hambsch J., Schneider P., Tarnok A. Soluble endothelial adhesion molecule concentration in patients with aortic coarctation. Endothelium. 2006; 13 (5): 353–8. DOI: 10.1080/10623320600972143
  24. Andrys C., Pozler O., Krejsek J., Derner V., Drahosova M., Kopecky O. Serum soluble adhesion molecules (sICAM-1, VCAM-1, E-selectin) in healthy school aged children and adults. Acta Med. 2000; 43 (3): 103–6.
  25. Keyloun J.W., Le T.D., Pusateri A.E., Ball R.L., Carney B.C., Orfeo Th. et al. Circulating syndecan-1 and tissue factor pathway inhibitor, biomarkers of endothelial dysfunction, predict mortality in burn patients. Shock. 2021; 56 (2): 237–44. DOI: 10.1097/SHK.0000000000001709
  26. Kitagawa Yu., Kawamura I., Suzuki K., Okada H., Ishihara T., Tomita H. et al. Serum syndecan-1 concentration in hospitalized patients with heart failure may predict readmission-free survival. PLoS ONE. 2021; 16 (12): e0260350. DOI: 10.1371/journal.pone.0260350
  27. Fukai N., Kenagy R.D., Chen L., Gao L., Daum G., Clowes A.W. Syndecan-1 an inhibitor of arterial smooth muscle cell growth and intimal hyperplasia. Arterioscler. Thromb. Vasc. Biol. 2009; 29: 1356–62. DOI: 10.1161/ATVBAHA.109.190132
  28. Astapenko D., Ticha A., Tomasova A., Hyspler R., Zadakb Z., Lehmanne Ch., Cerny V. Evaluation of endothelial glycocalyx in healthy volunteers – an observational study. Clin. Hemorheol. Microcirc. 2020; 75 (3): 257–65. DOI: 10.3233/CH-190581
  29. Saleh N., Khattab A., Rizk M., Salem S., Abo-Haded H. Value of galectin-3 assay in children with heart failure secondary to congenital heart diseases: a prospective study. BMC Pediatrics. 2020; 20: 537. DOI: 10.1186/s12887-020-02427-9
  30. Baggen V.J.M., van den Bosch A.E., Eindhoven J.A., Menting M.E., Witsenburg M., Cuypers J.A.A.E. et al. Prognostic value of galectin-3 in adults with congenital heart disease. Heart. 2018; 104: 394–400. DOI: 10.1136/heartjnl-2017-312070
  31. Mueller Th., Egger M., Leitner I., Gabriel Ch., Haltmayer M., Dieplinger B. Reference values of galectin-3 and cardiac troponins derived from a single cohort of healthy blood donors. Clin. Chim. Acta. 2016; 456: 19–23. DOI: 10.1016/j.cca.2016.02.014
  32. O’Rourke M.F., Cartmill T.B. Influence of aortic coarctation on pulsatile hemodynamics in the proximal aorta. Circulation. 1971; 44: 281–92. DOI: 10.1161/01.CIR.44.2.281
  33. James F.W., Kaplan S. Systolic hypertension during submaximal exercise after correction of coarctation of the aorta. Circulation. 1973; 49 (Suppl. II): II–27e34. DOI:10.1161/01.RES.34.1.27
  34. Freed M.D., Rocchini A., Rosenthal A., Nadas A.S., Castaneda A.R. Exercise-induced hypertension after surgical repair of coarctation of the aorta. Am. J. Cardiol. 1979; 43: 253–8. DOI: 10.1016/s0002-9149(79)80012-0
  35. Simsolo R., Grunfeld B., Gimenez M., Lopez M., Berri G., Becu L. et al. Long-term systemic hypertension in children after successful repair of coarctation of the aorta. Am. Heart J. 1988; 115: 1268–73. DOI: 10.1016/0002-8703(88)90020-8
  36. Krüger C., Rauh M., Dörr H.G. Immunoreactive renin concentrations in healthy children from birth to adolescence. Clin. Chim. Acta. 1998; 274 (1): 15–27. DOI: 10.1016/s0009-8981(98)00044-8
  37. Pipkin F.B., Smales O.R.C., O’Callaghan M.J. Renin and angiotensin levels in children. Arch. Dis. Child. 1981; 56 (4): 298–302. DOI: 10.1136/adc.56.4.298
  38. Wang X., Khalil R.A. Matrix metalloproteinases, vascular remodeling, and vascular disease. Adv. Pharmacol. 2018; 81: 241–330. DOI: 10.1016/bs.apha.2017.08.002 39. Goffin L., Fagagnini S., Vicari A., Mamie C., Melhem H., Weder B. et al. Anti-MMP-9 antibody: a promising therapeutic strategy for treatment of inflammatory bowel disease complications with fibrosis. Inflamm. Bowel. Dis. 2016; 22 (9): 2041–57. DOI: 10.1097/MIB.0000000000000863
  39. Flamant M., Placier S., Dubroca C., Esposito B., Lopes I., Chatziantoniou C. et al. Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension. 2007; 50 (1): 212–8. DOI: 10.1161/HYPERTENSIONAHA.107.089631
  40. Kalani A., Pushpakumar S.B., Vacek J.C., Tyagi S.C., Tyagi N. Inhibition of MMP-9 attenuates hypertensive cerebrovascular dysfunction in Dahl salt-sensitive rats. Mol. Cell. Biochem. 2016; 413 (1–2): 25–35. DOI: 10.1007/s11010-015-2623-8
  41. O’Sullivan Sh., Medina C., Ledwidge M., Radomski M.W., Gilmer J.F. Nitric oxide-matrix metaloproteinase-9 interactions: biological and pharmacological significance NO and MMP-9 interactions. Biochim. Biophys. Acta. 2014; 1843 (3): 603–17. DOI: 10.1016/j.bbamcr.2013.12.006
  42. Mortlock S. Matrix metalloproteinase-9: defining a normal reference range. Sch. J. App. Med. Sci. 2016; 4 (11D): 4146– 150. https://www.survivingmold.com/Publications/MMP-9_ Documentation_of_Worldwide_Levels_-_Final_-6-24-2021.pdf (accessed December 23, 2022).

About Authors

  • Andrey A. Svobodov, Cardiovascular Surgeon, Dr. Med. Sci., Professor, Deputy Director; ORCID
  • Elena G. Levchenko, Dr. Med. Sci., Leading Researcher; ORCID
  • Mariya I. Chernenko, Resident Physician, Paediatric Cardiologist; ORCID

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


Sort by